ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION

<p>Up-to-date data on combination therapy of arterial hypertension in patients with chronic kidney disease are presented. Special attention is paid to the fixed combination of calcium antagonist lercanidipine and angiotensin-converting enzyme inhibitor enalapril.</p>

Bibliographic Details
Main Author: N. A. Dzhaiani
Format: Article
Language:English
Published: Столичная издательская компания 2015-09-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/29
_version_ 1797707189616377856
author N. A. Dzhaiani
author_facet N. A. Dzhaiani
author_sort N. A. Dzhaiani
collection DOAJ
description <p>Up-to-date data on combination therapy of arterial hypertension in patients with chronic kidney disease are presented. Special attention is paid to the fixed combination of calcium antagonist lercanidipine and angiotensin-converting enzyme inhibitor enalapril.</p>
first_indexed 2024-03-12T06:02:43Z
format Article
id doaj.art-5849f37753cc48c3ac97a291e90e3d9f
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-03-12T06:02:43Z
publishDate 2015-09-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-5849f37753cc48c3ac97a291e90e3d9f2023-09-03T03:56:15ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0110223824410.1234/1819-6446-2014-2-238-24429ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTIONN. A. Dzhaiani0Московский государственный медико-стоматологический университет им. А.И. Евдокимова<p>Up-to-date data on combination therapy of arterial hypertension in patients with chronic kidney disease are presented. Special attention is paid to the fixed combination of calcium antagonist lercanidipine and angiotensin-converting enzyme inhibitor enalapril.</p>http://www.rpcardio.ru/jour/article/view/29хроническая болезнь почеккомбинированная антигипертензивная терапияантагонист кальцияингибитор ангиотензинпревращающего фермента
spellingShingle N. A. Dzhaiani
ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
Рациональная фармакотерапия в кардиологии
хроническая болезнь почек
комбинированная антигипертензивная терапия
антагонист кальция
ингибитор ангиотензинпревращающего фермента
title ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
title_full ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
title_fullStr ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
title_full_unstemmed ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
title_short ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
title_sort advantages of combination therapy of hypertension with calcium channel blocker and angiotensin converting enzyme inhibitor in patients with impaired renal function
topic хроническая болезнь почек
комбинированная антигипертензивная терапия
антагонист кальция
ингибитор ангиотензинпревращающего фермента
url http://www.rpcardio.ru/jour/article/view/29
work_keys_str_mv AT nadzhaiani advantagesofcombinationtherapyofhypertensionwithcalciumchannelblockerandangiotensinconvertingenzymeinhibitorinpatientswithimpairedrenalfunction